Judge Decides in Favor of Qiagen in Antitrust Claim

By Labmedica staff writers
Posted on 05 Feb 2008

Qiagen Gaithersburg, Inc. (formerly Digene Corp.), a wholly owned subsidiary of Qiagen (Frankfurt, Germany), announced that it was granted summary judgment on the antitrust counterclaims asserted against it in its patent infringement suit against Third Wave Technologies, Inc. (Madison, WI, USA).

Judge Barbara B. Crabb of the U.S. District Court for the Western District of Wisconsin ruled that Third Wave had "failed to show any violations,” by Qiagen of antitrust laws.

Peer Schatz, CEO of Qiagen, stated that the ruling makes it clear that "Qiagen's leadership in the marketplace for HPV [human papillomavirus] testing is the result of the trust we have earned with our customers based on the quality and performance of our molecular diagnostic solutions for HPV, our product's overwhelming clinical validation, and the fact that we are the first and only company to have received U.S. Food and Drug Administration (FDA; Rockville, MD, USA) approval for our molecular HPV test.”

Mr. Schatz added that the company would continue to aggressively pursue its pending patent litigation, in which Qiagen alleges that Third Wave is infringing on Qiagen intellectual property.

Related Links:
Qiagen
Third Wave Technologies